SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Stuart A Rushworth, Genevra Pillinger, Amina Abdul-Aziz, Rachel Piddock, Manar S Shafat, Megan Y Murray, Lyubov Zaitseva, Matthew J Lawes, David J MacEwan, Kristian M Bowles, Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells, The Lancet Haematology, 2015, 2, 5, e204

    CrossRef

  2. 2
    Magdalena Witkowska, Piotr Smolewski, Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma, Immunotherapy, 2015, 7, 1, 37

    CrossRef

  3. 3
    Minh Q. Huynh, Jennifer Goßmann, Stefan Gattenlöehner, Wolfram Klapper, Hans-Heinrich Wacker, Annette Ramaswamy, Alwina Bittner, Ulrich Kaiser, Andreas Neubauer, Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma, Leukemia & Lymphoma, 2015, 56, 4, 1088

    CrossRef

  4. 4
    Megan Y Murray, Lyubov Zaitseva, Martin J Auger, Jenny I O Craig, David J MacEwan, Stuart A Rushworth, Kristian M Bowles, Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma, Cell Cycle, 2015, 00

    CrossRef

  5. 5
    Y Wang, LL Zhang, RE Champlin, ML Wang, Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies, Clinical Pharmacology & Therapeutics, 2015, 97, 5
  6. 6
    K H Shain, W S Dalton, J Tao, The tumor microenvironment shapes hallmarks of mature B-cell malignancies, Oncogene, 2015,

    CrossRef

  7. 7
    Bryan R Lanning, Landon R Whitby, Melissa M Dix, John Douhan, Adam M Gilbert, Erik C Hett, Theodore O Johnson, Chris Joslyn, John C Kath, Sherry Niessen, Lee R Roberts, Mark E Schnute, Chu Wang, Jonathan J Hulce, Baoxian Wei, Laurence O Whiteley, Matthew M Hayward, Benjamin F Cravatt, A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors, Nature Chemical Biology, 2014, 10, 9, 760

    CrossRef

  8. 8
    Paul T. Bremer, Mark S. Hixon, Kim D. Janda, Benzoquinones as inhibitors of botulinum neurotoxin serotype A, Bioorganic & Medicinal Chemistry, 2014, 22, 15, 3971

    CrossRef

  9. 9
    Prithviraj Bose, Michael S Batalo, Beata Holkova, Steven Grant, Bortezomib for the treatment of non-Hodgkin’s lymphoma, Expert Opinion on Pharmacotherapy, 2014, 15, 16, 2443

    CrossRef

  10. 10
    Jiao Ma, Pin Lu, Ailin Guo, Shuhua Cheng, Hongliang Zong, Peter Martin, Morton Coleman, Y. Lynn Wang, Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells, British Journal of Haematology, 2014, 166, 6
  11. 11
    M Axelrod, Z Ou, L K Brett, L Zhang, E R Lopez, A T Tamayo, V Gordon, R J Ford, M E Williams, L V Pham, M J Weber, M L Wang, Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphoma, Leukemia, 2014, 28, 2, 407

    CrossRef

  12. 12
    M A Dengler, A Weilbacher, M Gutekunst, A M Staiger, M C Vöhringer, H Horn, G Ott, W E Aulitzky, H van der Kuip, Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles’ heel in mantle cell lymphoma, Cell Death and Disease, 2014, 5, 1, e1013

    CrossRef

  13. 13
    Aileen Novero, Pavan M Ravella, Yamei Chen, George Dous, Delong Liu, Ibrutinib for B cell malignancies, Experimental Hematology & Oncology, 2014, 3, 1, 4

    CrossRef

  14. 14
    S. A. Rushworth, M. Y. Murray, L. Zaitseva, K. M. Bowles, D. J. MacEwan, Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia, Blood, 2014, 123, 8, 1229

    CrossRef

  15. 15
    Megan Y. Murray, Martin J. Auger, Kristian M. Bowles, Overcoming bortezomib resistance in multiple myeloma, Biochemical Society Transactions, 2014, 42, 4, 804

    CrossRef

  16. 16
    Leo I. Gordon, Steven H. Bernstein, Pedro Jares, Brad S. Kahl, Thomas E. Witzig, Martin Dreyling, Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop, Leukemia & Lymphoma, 2014, 55, 10, 2262

    CrossRef

  17. 17
    Munevver Cinar, FaridSaei Hamedani, Zhicheng Mo, Bekir Cinar, Hesham M. Amin, Serhan Alkan, Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis, Leukemia Research, 2013, 37, 10, 1271

    CrossRef

  18. 18
    Liang Zhang, Kate J Newberry, Michael Wang, Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment, Expert Review of Clinical Immunology, 2013, 9, 6, 495

    CrossRef

  19. 19
    L. Vargas, A. Hamasy, B. F. Nore, C. I. E. Smith, Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases, Scandinavian Journal of Immunology, 2013, 78, 2
  20. 20
    Simone Ferrero, Martin Dreyling, The current therapeutic scenario for relapsed mantle cell lymphoma, Current Opinion in Oncology, 2013, 25, 5, 452

    CrossRef

  21. 21
    Clemens-Martin Wendtner, There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma, Leukemia & Lymphoma, 2013, 54, 11, 2343

    CrossRef